Item 8.01 Other Events.

On January 26, 2021, Apellis Pharmaceuticals, Inc. (the "Company") closed its previously announced privately negotiated exchange (the "Exchange Transactions") with certain holders of its 3.500% Convertible Senior Notes due 2026 (the "Notes") issued on September 16, 2019.

In the Exchange Transactions, the holders exchanged approximately $126.1 million in aggregate principal amount of Notes and the Company issued an aggregate of 3,906,869 shares of its common stock.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          Press Release of Apellis Pharmaceuticals, Inc., dated January 26, 2021

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses